Heart failure & cardiomyopathies
Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis
Authors' conclusion
LA function improved with tafamidis treatment in ATTRwt-CA patients with SR but not left ventricular function. However, these cardiac functions did not improve with tafamidis treatment in ATTRwt-CA patients with AF.
Study context
- Population
- Patients with biopsy-confirmed wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) treated with tafamidismean age 76 years
- Participants
- 23 patients
- Exposure
- Before vs 1 year after starting tafamidis, sinus rhythm (SR) vs atrial fibrillation (AF)
- SRn = 16
- AFn = 7
- Outcome
- LA and LV function by 2D speckle-tracking echocardiography (LA reservoir strain, GLS)
- Follow-up
- 1 year of treatment
Methodological detailssingle-group before–after comparison
- Single-group before–after comparison
Main finding
As reported in the abstract
before vs 1 year after starting tafamidis
| Group | Left atrial (LA) reservoir strain | Global longitudinal strain (GLS) |
|---|---|---|
| SR | 10.5 ± 5.0% to 11.9 ± 5.3%, P = 0.0307 | −10.6 ± 3.1% to −11.3 ± 3.0%, P = 0.0608 |
| AF | 5.4 ± 2.9% to 4.9 ± 1.7%, P = 0.4571 | −8.4 ± 2.3% to −6.8 ± 1.4%, P = 0.0267 |
Left atrial (LA) reservoir strain
SR10.5 ± 5.0% to 11.9 ± 5.3%, P = 0.0307
AF5.4 ± 2.9% to 4.9 ± 1.7%, P = 0.4571
Global longitudinal strain (GLS)
SR−10.6 ± 3.1% to −11.3 ± 3.0%, P = 0.0608
AF−8.4 ± 2.3% to −6.8 ± 1.4%, P = 0.0267
Observational data: associations, not effects.
Original publication
Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. Published 18 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →